- Active not recruitingPHASE3
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
This study looks at a new medicine called sparsentan for IgA nephropathy (IgAN), a kidney disease. It compares sparsentan to a standard treatment (irbesartan) to see if it helps protect kidneys and reduce protein in the urine over about two years.
For: Immunoglobulin A NephropathyUnited States · Australia · Belgium - RecruitingPHASE2
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
This study looks at a new drug, Sparsentan, for people with kidney disease called IgA Nephropathy. It aims to see if the drug is safe and helpful in protecting the kidneys, both for newly diagnosed patients and those who have had a kidney transplant.
For: Immunoglobulin A Nephropathy · Kidney Diseases · Glomerulonephritis, IGAUnited Kingdom - Active not recruitingPHASE2
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
This study looks at a new drug, sparsentan, for people with ANCA-associated vasculitis. It aims to see if blocking certain chemicals can help improve blood vessel health, which is important for preventing heart attacks and strokes in these patients.
For: ANCA Associated Vasculitis · Cardiovascular Diseases · Kidney DiseasesUnited Kingdom - RecruitingPHASE2
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
This study is looking at a new medicine called sparsentan for children aged 1 to 17 with certain kidney conditions like FSGS, MCD, IgAN, IgAV, and Alport Syndrome. It will check if the medicine is safe, works well, and how the body handles it over two years.
For: Focal Segmental Glomerulosclerosis · Minimal Change Disease · Immunoglobulin A NephropathyUnited States · Germany · Italy